---
document_datetime: 2025-06-12 11:52:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/rybrevant-epar-all-authorised-presentations_en.pdf
document_name: rybrevant-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8181402
conversion_datetime: 2025-12-28 05:35:34.48608
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form                   | Route of administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/21/1594/001 | Rybrevant         | 350 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 7 mL                      | 1 vial      |
| EU/1/21/1594/002 | Rybrevant         | 1600 mg    | Solution for injection                | Subcutaneous use          | vial (glass)          | 10 ml (160 mg/ml)         | 1 vial      |
| EU/1/21/1594/003 | Rybrevant         | 2240 mg    | Solution for injection                | Subcutaneous use          | vial (glass)          | 14 ml (160 mg/ml)         | 1 vial      |